Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 6/20 | 0.38 |
| ▸ | IRAK4 | Q9NWZ3 | 8/20 | 0.38 |
| ▸ | BRD4 | O60885 | 3/20 | 0.37 |
| ▸ | JAK2 | O60674 | 2/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13633970 | 1.00 | GPR119 (0.38) | GPR119HCRTR2IRAK4BRD4JAK2 | |
| SCHEMBL4521377 | 1.00 | GPR119 (0.38) | GPR119HCRTR2IRAK4BRD4JAK2 | |
| SCHEMBL4521371 | 1.00 | GPR119 (0.38) | GPR119HCRTR2IRAK4BRD4JAK2 | |
| SCHEMBL4521398 | 1.00 | GPR119 (0.38) | GPR119HCRTR2IRAK4BRD4JAK2 | |
| SCHEMBL4520162 | 1.00 | GPR119 (0.38) | GPR119HCRTR2IRAK4BRD4JAK2 | |
| SCHEMBL4521380 | 1.00 | GPR119 (0.38) | GPR119HCRTR2IRAK4BRD4JAK2 | |
| SCHEMBL4520849 | 0.88 | PAK1 (0.47) | GPR119HCRTR2IRAK4BRD4JAK2 | |
| SCHEMBL4520851 | 0.88 | PAK1 (0.47) | GPR119HCRTR2IRAK4BRD4JAK2 | |
| SCHEMBL4515048 | 0.88 | PAK1 (0.47) | GPR119HCRTR2IRAK4BRD4JAK2 | |
| SCHEMBL4535639 | 0.81 | ADORA2A (0.38) | GPR119HCRTR2IRAK4ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090281073-A1 | HETEROAROMATIC DERIVATIVES USEFUL AS ANTICANCER AGENTS | BHATTACHARYA SAMIT KUMAR | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281073-A1 | HETEROAROMATIC DERIVATIVES USEFUL AS ANTICANCER AGENTS | CCNY, TP53, CCNE1 | GPR119 1568/4885HCRTR2 3735/4885IRAK4 4490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.